PharmiWeb.com - Global Pharma News & Resources

Today Stories

TNB-486 will be evaluated in multiple types of lymphoma AstraZeneca today announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma1. The acquisition of TNB-486 aims to accelerate the development of this potential new medicine for B-cell haematologic malignancies, including diffuse large B-cell lymphoma and follicular lymphoma. Building on the success of Calquence (acalabrutinib), TNB-486 further diversifies AstraZeneca’s haematology pipeline that spans multiple therapeutic modalities and mechanisms to address a broad spectrum of blood cancers. TNB-486 belongs to a class of therapeutic antibodies known as T-cell engagers, which a…
Medicines, including insulin, to be available in 40 lower-income countries Investment fund established to help create sustainable health systems Announcements comes as Global Health stakeholders gather in Paris Paris – July 4, 2022 – Sanofi Global Health announces the launch of Impact®, a new brand of standard of care medicines produced by Sanofi dedicated for nonprofit distribution to at-risk populations in the world’s most impoverished countries. The Impact® brand, which includes insulin, glibenclamide and oxaliplatin amonst others, will enable the secure distribution of 30 Sanofi medicines in 40 lower-income countries. Considered essential by the World Health Organization, the medicines cover a wide range of therapeutic areas, including diabetes, cardiovascular disease, tuberculosis,…
Paris, 30 June, 2022 - Atos, in agreement with the Wellcome Genome Campus in Cambridgeshire, UK, today announces the official opening of its global Life Sciences Centre of Excellence. The facility will provide scientists on campus, and global genome and bio-data institutes worldwide, early access to emerging technologies to support their research, helping to accelerate the process of bringing new drugs to market and delivering tangible societal benefits. The Atos Life Sciences Centre of Excellence is an exploration, discovery and co-creation instrument aimed at complementing the existing Campus compute facilities with access to leading-edge technologies, such as Quantum, High-Performance Computing, Edge Computing and AI, supported by Atos’ products, services and expertise in these sectors…
Interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the start of treatment. Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.[i]  These findings further offer insight into the treatment of migraine in real-world clinical practice…
invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), focused on research and development (R&D) and business development activities outside of China, and F-star Therapeutics, Inc. (“F-star”) (NASDAQ:FSTX), a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives, today announced that the companies have entered into a definitive agreement whereby invoX will acquire all of the issued and outstanding shares of F-star common stock for $7.12 per share. The proposed acquisition values F-star at approximately $161 million. The transaction has been unanimously approved by the invoX and F-star Boards of Directors and is expected to close in the…
Scientific Laboratory Supplies (SLS) – the leading supplier of equipment, chemicals and consumables for laboratory use in the UK – has announced the acquisition of two businesses, Gem Scientific and Northern Balance, to expand its product and service offerings. Both companies will continue to operate as independent entities and retain all employees, whilst harnessing SLS’s business support and infrastructure to benefit all parties, stakeholders and customers.   Gem Scientific is a laboratory equipment distributor based in West Yorkshire, supplying high quality products – including hygiene testing devices and consumables – to sectors such as the food and beverage industry. This acquisition will help to strengthen both brands in this field, giving customers greater access to a wider range of…
Manufacturing facility would provide access to domestically manufactured vaccines against respiratory viruses Moderna would expand its presence in the UK through investments in R&D activities and capabilities Collaboration would support the UK with direct access to rapid pandemic response capabilities CAMBRIDGE, MA / ACCESSWIRE / June 21, 2022 / Moderna, Inc . (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement in principle with the United Kingdom government to establish an mRNA Innovation and Technology Center in the UK. This state-of-the-art mRNA vaccine manufacturing facility is expected to provide access to rapid pandemic response capabilities and Moderna's respiratory virus vaccine candidates. Additionall…
The Cell and Gene Therapy Catapult (CGT Catapult) and the UK Dementia Research Institute (UK DRI) today announce a collaboration to accelerate the clinical development of adeno-associated virus (AAV) based gene therapies for dementia. Since 2015, dementia has been one of the leading causes of mortality in the UK. Whilst new and improved treatments for heart disease and cancer are reducing mortality, a lack of effective treatment options for neurodegenerative conditions means that dementia-related deaths continue to rise. Through this collaboration, the CGT Catapult will work with UK academic centres of excellence and the UK DRI to identify new AAV-based gene therapies with high potential to become new medicines for dementia, assessing a wide range of assets in order to best address the sig…
Pfizer will invest €90.5 million in Valneva Planned Phase 3 study confirmed to initiate in Q3 2022 SAINT-HERBLAIN, France & NEW YORK--(BUSINESS WIRE)-- Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced that they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15. As previously announced on April 26, 2022, Pfizer plans to initiate the Phase 3 study of VLA15 in the third quarter of 2022. As part of the Equity Subscription Agreement, Pfizer will invest €90.5 ($95) million in Valneva, representing 8.1% of Valneva’s share capital at a price of €9.49 per share, through a reserved capital increase to further s…
Alliances with CVS Health and Javara further embed clinical research into the community healthcare setting, expanding access to patient populations across the U.S. to increase diversity in clinical trials BOSTON, and Durham, N.C., June 16, 2022 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO), today announced the launch of its Community Alliance Network, a novel program further integrating clinical research into the community healthcare setting to better serve patients and in turn create further opportunity for increased diversity in clinical trials. CVS Health®, the leading health care solutions company, and Javara, the leading Integrated Research Organization, have joined the network as inaugural members, opening the door to community-based research site…
Leading contract research organisation (CRO) Cellomatics Biosciences has moved into new purpose-built premises in Nottingham in the wake of rising demand for its bespoke preclinical and early drug discovery phase laboratory services. The company’s new facilities in Colwick, Nottingham represent a three-fold increase in the company’s footprint, allowing room for further expansion. The purpose-built facility is an independent building covering approximately 5,500 sq ft of space across two levels. The ground floor is dedicated to laboratory facilities, whilst the first floor provides scientific write-up space, offices, and meeting rooms. The new laboratories are equipped with state-of-the-art imaging and analysis equipment and Class ll biological safety cabinets, fridges, freezers, and CO2 in…
Ingelheim, Germany and San Diego, CA, June 14, 2022 – Boehringer Ingelheim today announced the signing of an option to acquire Trutino Biosciences Inc. (the “Transaction”), a San Diego-based biotech company.   Trutino Biosciences is a pre-clinical stage biotech company dedicated to the discovery and development of next-generation cytokine therapies to treat immuno-oncology and autoimmune diseases. Boehringer Ingelheim is dedicated to a two-pronged research strategy to fight cancers: through cancer cell-directed and immune cell-targeting compounds. The ongoing research partnership between Boehringer Ingelheim and Trutino is part of an overarching effort to mobilize a patient’s immune system to fight cancer.  Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery…
STRATEGIC PARTNERSHIP LEVERAGES EVOTEC’S PROPRIETARY PLATFORM CAPABILITIES IN THE FIELD OF PROTEIN HOMEOSTASIS Hamburg, Germany, 14 June 2022:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered a drug discovery collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Evotec’s innovative TargetAlloMod platforms will be evaluated to discover first-in-class novel mode of action therapeutic candidates. The agreement was facilitated by Johnson & Johnson Innovation.Under the agreement, Evotec and Janssen will jointly conduct screens on the identified targets and collaborate with hit identification and lead optimisation of the most promising…
Next-generation booster vaccine candidate delivers immune boost in adults primed with mRNA vaccines; with a stronger immune response compared to Pfizer-BioNTech’s Comirnaty booster vaccine Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile Paris – June 13, 2022 – Sanofi today reports data from two trials, VAT02 Cohort 2 and COVIBOOST VAT013, conducted with its new next-generation COVID-19 booster vaccine candidate modelled on the Beta variant antigen and including GSK’s pandemic adjuvant. In the Phase 3 VAT02 Cohort 2 study, the Sanofi-GSK next-generation vaccine candidate induced (at day 15 post-immunization) a significant boost in antibody tit…
Coave Therapeutics and ABL enter into strategic collaboration to develop gene therapy manufacturing processes and create joint capabilities for process development of AAV-based gene therapy Two-stage collaboration aims to accelerate development of high-capacity manufacturing processes for AAV-based products and secure Coave’s infrastructure needs to set up its process development capabilities Paris and Strasbourg, France, June 9, 2022 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, and ABL, a pure play contract development and manufacturing organization (CDMO) specialized in the development and manufacturing of viruses for vaccine candidates, gene and cancer therap…
WILMINGTON, N.C., June 08, 2022 - The PPD clinical research business of Thermo Fisher Scientific has been named Clinical Research Company of the Year at the 2022 PharmaTimes Clinical Researcher of the Year International competition held recently in London. In addition to the business winning the highest honor again this year, 50 clinical researchers from the company were named finalists within all nine eligible team and individual competition categories. "For the third year in a row, our colleagues have made their presence known by winning multiple recognitions, including the top title, in this highly regarded competition," said Amber Lee, senior vice president, clinical operations, clinical research, Thermo Fisher Scientific. "The unwavering dedication, expertise and passion our colleague…
Innovative Trials, a UK-based clinical trials patient recruitment company, has today (Monday 6 June) announced its intention to help fund research into multiple sclerosis (MS) and contribute towards the MS Society's vision of a world free from the effects of MS. The company, which works with some of the world’s biggest pharmaceutical companies to accelerate the development of life-changing treatments, has chosen the MS Society as its official 2022-23 charity partner and is aiming to raise at least £3,000 for the charity over the next 12 months.  MS is a neurological condition that affects nerves in the body. More than 130,000 people in the UK are living with the condition and around 7,000 people are diagnosed every year [1]. MS is unpredictable and different for everyone, but common sympto…
Expansion will create more than 250 additional high-skilled manufacturing jobs at Pfizer’s Kalamazoo site NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Michigan, facility, enabling U.S.-based production in support of its COVID-19 oral treatment, PAXLOVIDTM (nirmatrelvir [PF-07321332] tablets and ritonavir tablets). The investment will expand the production of active pharmaceutical ingredient (API) and registered starting materials (RSMs) used in the manufacture of nirmatrelvir, a novel main protease (Mpro) inhibitor originating in Pfizer’s laboratories, which will create more than 250 additional high-skilled jobs at Pfizer’s Kalamazoo site.…
Cambridge, UK, June 6, 2022 – SMC Ltd., a leading solutions provider in the manufacturing of pharmaceutical and medical devices, announces the opening of Cambridge Pharma, a new business offering pharmaceutical development services, including sterile fill-finish. The new 20,000 sq ft facility, located at the Cambridge Research Park, UK, includes a purpose-built sterile fill-finish facility, a process development laboratory and an analytical laboratory. Services include process development and scale up, sterile fill finish for clinical trials, QC and stability testing and QP release of clinical trials supplies. Chetan N. Patel, Owner and CEO of SMC Group, has a strategic vision for the Company, “We value pharmaceutical partnerships and continue to expand services in development, manufacturi…
On 23 June 2021 at its Investor Update, GSK plc (“GSK” or the “Company”) confirmed its intention to separate its Consumer Healthcare business from the GSK Group to form Haleon plc (“Haleon”), an independent listed company. It is proposed that the separation will be effected by way of a demerger (the “Demerger”) of at least 80 per cent. of GSK’s 68 per cent. holding in the Consumer Healthcare business to GSK shareholders. The Consumer Healthcare business is currently a joint venture between GSK and Pfizer Inc (“Pfizer”), with GSK holding a majority controlling interest of 68 per cent. and Pfizer holding 32 per cent. GSK today confirms that the Circular in relation to the proposed Demerger, the consolidation of GSK shares (the “GSK Share Consolidation”) and certain new arrangements with Hal…